Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$2.85
+3.6%		$3.34
$2.32
▼
$5.46
$96.96M0.51193,213 shs64,507 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.12
+1.1%		$3.90
$2.05
▼
$15.15
$3.36M0.66191,857 shs8,828 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-2.83%-9.84%-14.60%+11.34%-8.94%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-2.33%-14.29%-41.01%-68.33%-78.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$2.85
+3.6%		$3.34
$2.32
▼
$5.46
$96.96M0.51193,213 shs64,507 shs
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$2.12
+1.1%		$3.90
$2.05
▼
$15.15
$3.36M0.66191,857 shs8,828 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-2.83%-9.84%-14.60%+11.34%-8.94%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-2.33%-14.29%-41.01%-68.33%-78.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.40
Hold$10.00250.88% Upside
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest SILO and ANIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/21/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/19/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/21/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/1/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
6/30/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital logo
D. Boral Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$10.00
6/17/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/12/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/12/2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
6/11/2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$210K461.70N/AN/A$0.42 per share6.79
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
$70K48.25N/AN/A$7.10 per share0.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$10.93M-$0.31N/AN/AN/AN/A-75.93%-67.45%N/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$4.23M-$4.36N/AN/AN/A-6,726.39%-81.75%-66.35%N/A

Latest SILO and ANIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/9/2026Q3 2026
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.0818-$0.08+$0.0018-$0.08N/AN/A
8/13/2026Q2 2026
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
-$0.32-$0.76-$0.44-$0.76$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
9.79
9.79
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
N/A
5.36
5.36

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
29.13%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
5.58%

Insider Ownership

CompanyInsider Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
26.40%
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
3.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
534.02 million25.04 millionOptionable
Silo Pharma, Inc. stock logo
SILO
Silo Pharma
21.59 million1.53 millionNot Optionable

Recent News About These Companies

Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum
September 9 at 12:53 PM  |  rttnews.comhttps://www.rttnews.com/3689667/silo-pharma-to-highlight-spc-15-nose-to-brain-technology-at-2026-nasal-innovation-forum.aspx
Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development
September 9 at 9:31 AM  |  quiverquant.comQ
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
September 9 at 9:15 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358782/0/en/silo-pharma-to-highlight-patented-nose-to-brain-drug-delivery-technology-for-ptsd-at-2026-nasal-innovation-forum.html
Silo Pharma’s lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder receives Canadian patent
August 20, 2026  |  pharmabiz.comP
Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/silo-pharma-gets-canadian-patent-204920200.html
Silo Pharma Acquires Digital Assets via Stock Issuance
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/silo-pharma-acquires-digital-assets-via-stock-issuance?utm_source=marketbeat.com&utm_medium=referral
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
August 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/18/3347240/0/en/silo-pharma-receives-notice-of-allowance-for-canadian-patent-application-for-novel-ptsd-treatment.html
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/silo-pharma-granted-european-patent-covering-novel-ptsd-therapy-1036435534
Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy
August 10, 2026  |  quiverquant.comQ
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
August 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/06/3340312/0/en/silo-pharma-subsidiary-qwikagents-collaborates-with-amazon-web-services-premier-tier-partner-caylent-to-advance-enterprise-ai-platform.html
Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development
July 21, 2026  |  quiverquant.comQ
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330474/0/en/silo-pharma-advances-growth-platforms-for-ai-agent-commercialization-and-lead-ptsd-drug-program.html
Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?
July 15, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-silo-pharma-inc-silo-stock-an-ai-opportunity-after-nvidia-partnership-boosts-qwikagents-platform-1801641/
Silo Pharma’s QwikAgents joins AMD AI developer program to advance AI agent platform
July 14, 2026  |  msn.comhttps://www.msn.com/en-us/technology/software/silo-pharma-s-qwikagents-joins-amd-ai-developer-program-to-advance-ai-agent-platform/ar-AA27UgLT
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
July 14, 2026  |  benzinga.comhttps://www.benzinga.com/news/health-care/26/07/60447743/silo-pharma-unit-eyes-faster-ai-agent-development-through-amd-partnership?utm_source=snapi
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
July 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/14/3326873/0/en/silo-pharma-s-qwikagents-joins-amd-ai-developer-program-to-advance-enterprise-ai-agent-platform.html
CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall
July 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ccc-intelligent-solutions-circle-rise-125702837.html
Silo Pharma Sinks on Stock Sale
July 10, 2026  |  baystreet.cahttps://www.baystreet.ca/stockstowatch/23630/Silo-Pharma-Sinks-on-Stock-Sale
Silo Pharma shares slide after announcing up to $11.7 million private placement (SILO)
July 10, 2026  |  msn.comhttps://www.msn.com/en-us/travel/news/silo-pharma-shares-slide-after-announcing-up-to-117-million-private-placement-silo/ar-AA27Essb
Silo Pharma Announces $4 Million Private Placement with Up to Approximately $7.7 Million in Potential Additional Gross Proceeds from Warrants
July 10, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$2.85 +0.10 (+3.64%)
As of 10:55 AM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Silo Pharma stock logo

Silo Pharma NASDAQ:SILO

$2.12 +0.02 (+1.14%)
As of 11:14 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas